A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Tulisokibart (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme
- 24 Oct 2024 New trial record